Half of people who start taking the GLP-1 weight-loss drug Ozempic drop it within a year, a new study says.
About 52% of people in Denmark prescribed semaglutide (Ozempic, Wegovy) for weight loss stopped taking it after one year, researchers reported Saturday at a meeting of the European Association for the Study of Diabetes in Vienna.
The drugs' high cost appears to be the reason why people give them only a brief try, researchers said.
"This level of drop off is concerning because these medications aren't meant to be a temporary quick fix," lead author Dr. Reimar Thomsen, a professor of metabolic disease epidemiology at Aarhus University Hospital in Denmark, said in a news release.
Related
